Interstitial Lung Disease Treatments
Find Interstitial Lung Disease Treatments
Treatment Overview
Living with interstitial lung disease (ILD) often means adjusting to a “new normal” regarding physical activity and energy levels. The hallmark symptom, shortness of breath can turn simple tasks like climbing stairs or walking to the mailbox into a challenge. This group of disorders causes scarring (fibrosis) and inflammation in the tissues that support the air sacs, making it harder for the lungs to expand and deliver oxygen to the bloodstream. The diagnosis can feel isolating, but understanding the treatment landscape provides a roadmap for managing the condition.
Treatment is essential to slow the progression of lung damage, reduce active inflammation, and maintain quality of life. While some lung scarring is permanent, therapy aims to preserve the remaining healthy lung tissue and improve breathing capacity. Because ILD encompasses over 200 different disorders, ranging from idiopathic pulmonary fibrosis to autoimmune-related lung disease, treatment plans vary significantly. A doctor will tailor the medication regimen based on the specific cause, the degree of inflammation versus scarring, and the patient’s overall health (National Heart, Lung, and Blood Institute, 2023).
Overview of treatment options for Interstitial Lung Disease
The primary goal of treating ILD is to halt or slow the disease process. Treatment strategies generally fall into two categories: anti-inflammatory therapies for conditions driven by an overactive immune system, and antifibrotic therapies for conditions primarily defined by scarring.
For acute flare-ups or inflammatory types of ILD (such as sarcoidosis or hypersensitivity pneumonitis), doctors focus on suppressing the immune response. For chronic, progressive scarring conditions like idiopathic pulmonary fibrosis (IPF), the focus shifts to slowing the rate of fibrosis. While medications are the cornerstone of management, they are often combined with supportive measures like supplemental oxygen and pulmonary rehabilitation to maximize physical function. In severe cases where medications are no longer effective, lung transplantation may be considered.
Medications used for Interstitial Lung Disease
Corticosteroids are typically the first-line treatment for ILDs caused by inflammation or autoimmune disorders. Prednisone is the most common example. These drugs are often started at higher doses to quickly bring inflammation under control and then tapered down to the lowest effective dose.
When corticosteroids are needed long-term, or if they are not effective enough on their own, doctors often introduce immunosuppressants (also called steroid-sparing agents). Medications such as mycophenolate mofetil and azathioprine suppress the immune system’s attack on the lungs. Studies show that these agents can help stabilize lung function in patients with connective tissue disease-associated ILD while reducing the need for high-dose steroids.
For ILDs characterized by progressive scarring, such as IPF, antifibrotic medications are the standard of care. There are two main FDA-approved drugs in this class: nintedanib and pirfenidone. These medications do not remove existing scar tissue, but clinical experience suggests they significantly slow the rate at which lung function declines. Patients taking antifibrotics often continue them indefinitely to preserve lung capacity (Pulmonary Fibrosis Foundation, 2024).
How these medications work
Corticosteroids and immunosuppressants work by calming the body’s immune response. In many types of ILD, white blood cells mistakenly attack the lung tissue, causing swelling and eventual damage. By inhibiting the production and activity of these immune cells, these drugs reduce the inflammation that leads to scarring.
Antifibrotic medications target the specific biological pathways involved in scar formation. When the lungs are injured, the body attempts to repair them, but in ILD, this repair process goes awry and creates excessive fibrous tissue. Nintedanib and pirfenidone block the growth factors and chemical signals that tell cells to produce collagen and scar tissue. This helps keep the lung tissue softer and more flexible for longer (Mayo Clinic, 2023).
Side effects and safety considerations
Long-term corticosteroid use risks include weight gain, high blood sugar, osteoporosis, and mood changes, requiring close medical monitoring. Immunosuppressants increase infection risk by lowering immunity; regular blood tests track liver function and white blood cells.
Antifibrotic drugs commonly cause GI side effects (nausea, diarrhea, appetite loss). Pirfenidone also causes sun sensitivity, necessitating high-SPF sunscreen and protective clothing. Patients must seek immediate care for signs of infection (fever/chills) or sudden, worsening shortness of breath.
Since everyone’s experience with the condition and its treatments can vary, working closely with a qualified healthcare provider helps ensure safe and effective care.
References
- Mayo Clinic. https://www.mayoclinic.org
- National Heart, Lung, and Blood Institute. https://www.nhlbi.nih.gov
- Pulmonary Fibrosis Foundation. https://www.pulmonaryfibrosis.org
- American Lung Association. https://www.lung.org
Medications for Interstitial Lung Disease
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Interstitial Lung Disease.